Application of a LC-MS/MS method for evaluating lung penetration of tobramycin in rats by microdialysis.
A bioanalytical LC-MS/MS method was developed and validated to determine tobramycin in plasma and lung microdialysate samples. Tobramycin was separated using a C18column and a mobile phase consisting of water and acetonitrile, both with 10mM of heptafluorobutyric acid, eluted as gradient. Apramycin was used as internal standard (IS) for plasma samples. Drugs were monitored using electrospray ionization operating on positive mode (ESI+) monitoring the transitions 468.2>163.3 m/z for tobramycin and 540.3>217.2 m/z for IS. The method showed linearity in the concentration range of 0.1-50μgmL-1for microdialysate and 0.5-100μgmL-1for plasma with coefficients of determination ≥0.991. The inter- and intra-day precision, the accuracy and the stability of the drug in different conditions were in accordance with the limits established by US Food and Drug Administration guideline. The concentrations of tobramycin in plasma and lung microdialysate, determined using CMA/20 probes and a Ringer solution at a flow rate of 1μLmin-1, were evaluated in healthy Wistar rats after a 10mgkg-1i.v. bolus dose. Samples were harvested up to 12h post-dose. Before animal's experiments, probe recovery was determined by dialysis and retrodialysis in vitro and by retrodialysis in vivo. Probes recovery was independent of drug concentration and method of determination. In vivo recovery was 27.74±7.70%. Pharmacokinetic parameters were estimated by non-compartmental analysis using the software Phoenix®. The estimated area under the curve (AUC0-∞) was 128±19μghmL-1and 105±12μghmL-1for plasma and lung, respectively. Tobramycin plasma clearance was 0.07±0.01L/h/kg and the volume of distribution was 0.49±0.09L/kg. Elimination half-life in plasma was 4.4±0.7h and in lung, 4.2±0.56h. The free tissue/free plasma AUC0-∞ratio was 0.94. This is the first study showing a validated method to quantify tobramycin in microdialysate samples and to evaluate the lung interstitial concentration of the drug.
Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil; Bioanalytical Drugs Centre, College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
P M
PM
Bernardi
Laboratório Nacional Agropecuário do Rio Grande do Sul (LANAGRO/RS), Porto Alegre, RS, Brazil.
F
F
Barreto
Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil; Bioanalytical Drugs Centre, College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: dalla.costa@ufrgs.br.
T
T
Dalla Costa
D000818:Animals; D000900:Anti-Bacterial Agents / Q000032:analysis / Q000097:blood*; D002853:Chromatography, Liquid / Q000379:methods; D008168:Lung / Q000378:metabolism*; D008297:Male; D017551:Microdialysis / Q000379:methods*; D051381:Rats; D017208:Rats, Wistar; D053719:Tandem Mass Spectrometry / Q000379:methods*; D014031:Tobramycin / Q000032:analysis / Q000097:blood*
D000900:Anti-Bacterial Agents; D014031:Tobramycin
Bioanalytical method validation; LC–MS/MS; Microdialysis; Pre-clinical pharmacokinetics; Tissue penetration; Tobramycin